Literature DB >> 19485993

The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures.

Tet L Yap1, Christian Brown, David A Cromwell, Jan van der Meulen, Mark Emberton.   

Abstract

OBJECTIVE: To assess the effect of a self-management programme (SMP) on actual voiding behaviour using frequency-volume chart (FVC) data. PATIENTS AND METHODS: In all, 140 men with uncomplicated lower urinary tract symptoms (LUTS) were recruited and randomised to either attend a SMP in addition to standard care, or standard care alone. The SMP group received three small group sessions that addressed behaviour and gave training in problem-solving strategies. Patients were assessed in urological clinics at baseline and 3, 6 and 12 months, completing the International Prostate Symptom Score (IPSS) and 3-day FVCs after assessment. Differences in voiding behaviour between the SMP and control groups were calculated analysed by intention-to-treat.
RESULTS: Of the 140 patients, 104 completed the FVC data at baseline; at 3, 6 and 12 months charts were received from 99, 95 and 70, respectively. Baseline FVC variables were equivalent between the randomized groups. At 3 months the mean voided volume had increased in the SMP group and differed from the control group by a mean (95% confidence interval, CI) of 57 (33-83) mL. The total number of voids and episodes of nocturia were also lower in the SMP group, with a mean (95% CI) decrease of 2.6 (-3.6 to -1.5) and 0.7 (-1.1 to -0.3) episodes, respectively. These changes were maintained at 6 and 12 months.
CONCLUSION: A SMP in addition to standard care significantly improved the urinary symptoms of frequency and nocturia according to FVC monitoring. The exact mechanism of action and the specific interventions which affect this require further investigation.

Entities:  

Mesh:

Year:  2009        PMID: 19485993     DOI: 10.1111/j.1464-410X.2009.08497.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  12 in total

1.  Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men.

Authors:  Satoru Kira; Takahiko Mitsui; Tatsuya Miyamoto; Tatsuya Ihara; Hiroshi Nakagomi; Yuka Hashimoto; Hajime Takamatsu; Masayuki Tanahashi; Masahiro Takeda; Norifumi Sawada; Karl-Erik Andersson; Masayuki Takeda
Journal:  World J Urol       Date:  2019-01-23       Impact factor: 4.226

2.  Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction.

Authors:  Valter Silva; Antonio Jose Grande; Maria S Peccin
Journal:  Cochrane Database Syst Rev       Date:  2019-04-06

Review 3.  Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Jiye Kim; Roderick MacDonald; Balaji Reddy; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

4.  Comparison of effects of tamsulosin and silodosin on subfoveal choroidal thickness and pupil size diameters in patients with prostatic hyperplasia.

Authors:  Hatice Selen Kanar; Mahmut Taha Olcucu; Ibrahim Ozdemir
Journal:  Int Ophthalmol       Date:  2021-07-28       Impact factor: 2.031

Review 5.  Drugs for benign prostatic hypertrophy.

Authors:  Manasi Jiwrajka; William Yaxley; Sachinka Ranasinghe; Marlon Perera; Matthew J Roberts; John Yaxley
Journal:  Aust Prescr       Date:  2018-10-01

Review 6.  Current Treatment for Benign Prostatic Hyperplasia.

Authors:  Arkadiusz Miernik; Christian Gratzke
Journal:  Dtsch Arztebl Int       Date:  2020-12-04       Impact factor: 5.594

7.  TReatIng Urinary symptoms in Men in Primary Healthcare using non-pharmacological and non-surgical interventions (TRIUMPH) compared with usual care: study protocol for a cluster randomised controlled trial.

Authors:  Jessica Frost; J Athene Lane; Nikki Cotterill; Mandy Fader; Lucy Hackshaw-McGeagh; Hashim Hashim; Margaret Macaulay; Stephanie J MacNeill; Sian Noble; Jonathan Rees; Matthew J Ridd; Luke Robles; Gordon Taylor; Jodi Taylor; Marcus J Drake; Jo Worthington
Journal:  Trials       Date:  2019-09-02       Impact factor: 2.279

8.  Development of an online personalized self-management intervention for men with uncomplicated LUTS.

Authors:  Marco H Blanker; Pim Brandenbarg; Bart G C Slijkhuis; Martijn G Steffens; Michael R van Balken; Petra Jellema
Journal:  Neurourol Urodyn       Date:  2019-05-20       Impact factor: 2.696

9.  Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Authors:  Eu Chang Hwang; Shreyas Gandhi; Jae Hung Jung; Mari Imamura; Myung Ha Kim; Ran Pang; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2018-10-11

10.  Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria.

Authors:  Sangjun Yoo; Juhyun Park; Sung Yong Cho; Min Chul Cho; Hyeon Jeong; Hwancheol Son
Journal:  PLoS One       Date:  2018-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.